PT91420B - Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus - Google Patents
Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus Download PDFInfo
- Publication number
- PT91420B PT91420B PT91420A PT9142089A PT91420B PT 91420 B PT91420 B PT 91420B PT 91420 A PT91420 A PT 91420A PT 9142089 A PT9142089 A PT 9142089A PT 91420 B PT91420 B PT 91420B
- Authority
- PT
- Portugal
- Prior art keywords
- insulin
- arg
- core core
- formula
- treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 title abstract description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 37
- 102000004877 Insulin Human genes 0.000 claims abstract description 14
- 108090001061 Insulin Proteins 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims description 18
- 229940125396 insulin Drugs 0.000 claims description 14
- 101000976075 Homo sapiens Insulin Proteins 0.000 claims description 3
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 claims 1
- 108010005991 Pork Regular Insulin Proteins 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 239000002088 nanocapsule Substances 0.000 claims 1
- 239000011701 zinc Substances 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 6
- 150000003839 salts Chemical class 0.000 abstract description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract description 5
- 229910052725 zinc Inorganic materials 0.000 abstract description 5
- 239000004026 insulin derivative Substances 0.000 abstract description 4
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002349 favourable effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 101150035983 str1 gene Proteins 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- -1 -isopropyl ester Chemical class 0.000 description 1
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 240000003023 Cosmos bipinnatus Species 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000047352 Esterase-like Human genes 0.000 description 1
- 108700037229 Esterase-like Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100021496 Insulin-degrading enzyme Human genes 0.000 description 1
- 108090000828 Insulysin Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000287118 Parus Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3827533A DE3827533A1 (de) | 1988-08-13 | 1988-08-13 | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PT91420A PT91420A (pt) | 1990-03-08 |
| PT91420B true PT91420B (pt) | 1995-05-04 |
Family
ID=6360797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT91420A PT91420B (pt) | 1988-08-13 | 1989-08-10 | Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5177058A (https=) |
| EP (1) | EP0357978B1 (https=) |
| JP (1) | JPH02101022A (https=) |
| KR (1) | KR900002801A (https=) |
| AT (1) | ATE75945T1 (https=) |
| AU (1) | AU621648B2 (https=) |
| CA (1) | CA1332354C (https=) |
| DE (2) | DE3827533A1 (https=) |
| DK (1) | DK395689A (https=) |
| ES (1) | ES2039773T3 (https=) |
| FI (1) | FI95202C (https=) |
| GR (1) | GR3005326T3 (https=) |
| HU (1) | HU203670B (https=) |
| IE (1) | IE61266B1 (https=) |
| NO (1) | NO178914C (https=) |
| NZ (1) | NZ230280A (https=) |
| PT (1) | PT91420B (https=) |
| ZA (1) | ZA896149B (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875589B1 (en) * | 1988-06-23 | 2005-04-05 | Hoechst Aktiengesellschaft | Mini-proinsulin, its preparation and use |
| DE4024434A1 (de) * | 1990-08-01 | 1992-02-13 | Fresenius Ag | Vorrichtung zur ultrafiltrationskontrolle bzw. ultrafiltrationsregelung bei blutreinigungsverfahren |
| HU225496B1 (en) * | 1993-04-07 | 2007-01-29 | Scios Inc | Pharmaceutical compositions of prolonged delivery, containing peptides |
| US5534488A (en) * | 1993-08-13 | 1996-07-09 | Eli Lilly And Company | Insulin formulation |
| YU18596A (sh) * | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
| PT821006E (pt) | 1996-07-26 | 2004-09-30 | Aventis Pharma Gmbh | Derivados de insulina com ligacao a zinco aumentada |
| WO1999034821A1 (en) * | 1998-01-09 | 1999-07-15 | Novo Nordisk A/S | Stabilised insulin compositions |
| DE19825447A1 (de) | 1998-06-06 | 1999-12-09 | Hoechst Marion Roussel De Gmbh | Neue Insulinanaloga mit erhöhter Zinkbildung |
| DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| CZ2004710A3 (cs) * | 2001-12-20 | 2005-02-16 | Eli Lilly And Company | Inzulínová sloučenina s protrahovaným účinkem |
| DE10227232A1 (de) | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| EP1620465A2 (en) * | 2003-04-29 | 2006-02-01 | Eli Lilly And Company | Insulin analogs having protracted time action |
| CA2531988C (en) * | 2003-08-05 | 2016-06-28 | Novo Nordisk A/S | Novel insulin derivatives |
| RU2527893C2 (ru) * | 2004-07-19 | 2014-09-10 | Биокон Лимитед | Инсулин-олигомерные конъюгаты, их препараты и применения |
| ES2371361T3 (es) * | 2005-12-28 | 2011-12-30 | Novo Nordisk A/S | Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones. |
| JP5552046B2 (ja) * | 2007-06-13 | 2014-07-16 | ノボ・ノルデイスク・エー／エス | インスリン誘導体を含有する薬学的製剤 |
| RU2453332C2 (ru) * | 2007-10-16 | 2012-06-20 | Байокон Лимитид | Твердая фармацевтическая композиция (варианты) и способ контроля концентрации глюкозы с ее помощью, способ получения твердой фармацевтической композиции (варианты), таблетка (варианты) и способ получения амфорных частиц |
| RS59913B1 (sr) | 2008-10-17 | 2020-03-31 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
| JP4959005B2 (ja) * | 2008-10-30 | 2012-06-20 | ノボ・ノルデイスク・エー／エス | 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療 |
| CN102596175A (zh) | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
| MY180661A (en) | 2009-11-13 | 2020-12-04 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| PT3345593T (pt) | 2009-11-13 | 2023-11-27 | Sanofi Aventis Deutschland | Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina |
| PL2611458T3 (pl) | 2010-08-30 | 2017-02-28 | Sanofi-Aventis Deutschland Gmbh | Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2 |
| DK2632478T3 (da) | 2010-10-27 | 2019-10-07 | Novo Nordisk As | Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| EP2991672A1 (en) | 2013-04-30 | 2016-03-09 | Novo Nordisk A/S | Novel administration regime |
| EP3229828B1 (en) | 2014-12-12 | 2023-04-05 | Sanofi-Aventis Deutschland GmbH | Insulin glargine/lixisenatide fixed ratio formulation |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US12343383B2 (en) | 2019-07-12 | 2025-07-01 | Novo Nordisk A/S | High concentration insulin formulation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2143591A (en) * | 1936-09-26 | 1939-01-10 | Univ Alberta | Therapeutic preparation and process of making and using it |
| US2354211A (en) * | 1940-07-02 | 1944-07-25 | Burroughs Wellcome Co | Insulin preparation |
| DOP1982004086A (es) * | 1981-08-27 | 1988-03-22 | Lilly Co Eli | Formula farmaceutica que comprende insulina humana y proinsulina humana |
| DE3326472A1 (de) * | 1983-07-22 | 1985-02-14 | Hoechst Ag, 6230 Frankfurt | Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
| DE3326473A1 (de) * | 1983-07-22 | 1985-01-31 | Hoechst Ag, 6230 Frankfurt | Pharmazeutisches mittel zur behandlung des diabetes mellitus |
| DE3333640A1 (de) * | 1983-09-17 | 1985-04-25 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung |
| DE3334407A1 (de) * | 1983-09-23 | 1985-04-04 | Hoechst Ag, 6230 Frankfurt | In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus |
| DK113585D0 (da) * | 1985-03-12 | 1985-03-12 | Novo Industri As | Nye peptider |
| DK347086D0 (da) * | 1986-07-21 | 1986-07-21 | Novo Industri As | Novel peptides |
-
1988
- 1988-08-13 DE DE3827533A patent/DE3827533A1/de not_active Withdrawn
-
1989
- 1989-08-08 AT AT89114617T patent/ATE75945T1/de not_active IP Right Cessation
- 1989-08-08 EP EP89114617A patent/EP0357978B1/de not_active Expired - Lifetime
- 1989-08-08 ES ES89114617T patent/ES2039773T3/es not_active Expired - Lifetime
- 1989-08-08 DE DE8989114617T patent/DE58901401D1/de not_active Expired - Lifetime
- 1989-08-10 FI FI893783A patent/FI95202C/fi not_active IP Right Cessation
- 1989-08-10 PT PT91420A patent/PT91420B/pt not_active IP Right Cessation
- 1989-08-11 HU HU894148A patent/HU203670B/hu unknown
- 1989-08-11 ZA ZA896149A patent/ZA896149B/xx unknown
- 1989-08-11 DK DK395689A patent/DK395689A/da not_active Application Discontinuation
- 1989-08-11 KR KR1019890011430A patent/KR900002801A/ko not_active Withdrawn
- 1989-08-11 IE IE259489A patent/IE61266B1/en not_active IP Right Cessation
- 1989-08-11 NZ NZ230280A patent/NZ230280A/xx unknown
- 1989-08-11 NO NO893239A patent/NO178914C/no unknown
- 1989-08-11 US US07/392,559 patent/US5177058A/en not_active Expired - Lifetime
- 1989-08-11 AU AU39514/89A patent/AU621648B2/en not_active Expired
- 1989-08-11 JP JP1207057A patent/JPH02101022A/ja active Pending
- 1989-08-11 CA CA000608115A patent/CA1332354C/en not_active Expired - Lifetime
-
1992
- 1992-07-31 GR GR920401367T patent/GR3005326T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO893239L (no) | 1990-02-14 |
| US5177058A (en) | 1993-01-05 |
| AU621648B2 (en) | 1992-03-19 |
| DK395689D0 (da) | 1989-08-11 |
| EP0357978B1 (de) | 1992-05-13 |
| FI95202B (fi) | 1995-09-29 |
| FI893783L (fi) | 1990-02-14 |
| NO178914C (no) | 1996-07-03 |
| CA1332354C (en) | 1994-10-11 |
| NO178914B (no) | 1996-03-25 |
| ZA896149B (en) | 1990-04-25 |
| NZ230280A (en) | 1991-09-25 |
| FI893783A0 (fi) | 1989-08-10 |
| HUT50443A (en) | 1990-02-28 |
| ATE75945T1 (de) | 1992-05-15 |
| IE61266B1 (en) | 1994-10-19 |
| DE3827533A1 (de) | 1990-02-15 |
| KR900002801A (ko) | 1990-03-23 |
| HU203670B (en) | 1991-09-30 |
| ES2039773T3 (es) | 1996-07-16 |
| FI95202C (fi) | 1996-01-10 |
| IE892594L (en) | 1990-02-13 |
| JPH02101022A (ja) | 1990-04-12 |
| DE58901401D1 (de) | 1992-06-17 |
| NO893239D0 (no) | 1989-08-11 |
| EP0357978A1 (de) | 1990-03-14 |
| DK395689A (da) | 1990-02-14 |
| AU3951489A (en) | 1990-02-15 |
| PT91420A (pt) | 1990-03-08 |
| GR3005326T3 (https=) | 1993-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT91420B (pt) | Processo para a preparacao de uma composicao farmaceutica para o tratamento da diabetes mellitus | |
| KR930000861B1 (ko) | 오메프라졸 직장투여 조성물 | |
| AU712927B2 (en) | Pharmaceutical preparations comprised of salts of hyaluronic acid with local anaesthetics | |
| US5080893A (en) | Method for preventing surgical adhesions using a dilute solution of polymer | |
| JP2694166B2 (ja) | ゲル形成液体担体組成物 | |
| US6464970B1 (en) | Method and composition for preventing surgical adhesions | |
| US5350573A (en) | Method and composition for preventing surgical adhesions | |
| JP3779200B2 (ja) | ヒアルロン酸及び／又はその塩の水溶液の安定化組成物 | |
| US6858673B1 (en) | Composition for hydrogel, hydrogel and use thereof | |
| EP1203784B1 (en) | Polymer, in vivo degradable material, and use | |
| JP2006182750A (ja) | 凍結乾燥化粧品およびその製造方法 | |
| EP0319964B1 (en) | Film-formation-type antifungal preparation | |
| CA1341093C (en) | Method and composition for preventing surgical adhesions | |
| SE451666B (sv) | Stabil bensoylperoxidkomposition | |
| EP0315401A3 (en) | Xanthine derivatives and their preparation and pharmaceutical formulation | |
| HUT72413A (en) | Ortho-amine-substituted benzoyl-guanidine derivatives, process for producing them their pharmaceutical or diagnostical use, and pharmaceutical compositions containing them | |
| WO2021033898A1 (ko) | 침전으로부터 안정한 소듐디옥시콜레이트를 포함하는 수용액상 조성물 | |
| NO823420L (no) | Sulfonerte vinylaromatiske homopolymerer og kopolymerer som middel for hindring av plaque paa tenner | |
| DK166993B1 (da) | Anthelmintisk vandigt gelpraeparat til oral indgift, isaer af aelevamisolae og aetetremisolae, og fremgangsmaade til dets fremstilling. | |
| AU628114B2 (en) | Pharmaceutical composition for ophthalmic use comprising a water soluble acid addition salt of ibopamine | |
| JPS6281319A (ja) | 前眼部手術用の前房注入剤 | |
| Brown et al. | Effects of selective channel blocking agents on contractions and action potentials in K+‐depolarized guinea‐pig atria | |
| KR100214714B1 (ko) | 신규한 국소마취제 함유 겔제제 | |
| WO2014090889A1 (en) | Oral solutions comprising folic acid | |
| JPH07101866A (ja) | 腹腔内の癒着防止剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG3A | Patent granted, date of granting |
Effective date: 19941007 |
|
| MM4A | Annulment/lapse due to non-payment of fees, searched and examined patent |
Free format text: MAXIMUM VALIDITY LIMIT REACHED Effective date: 20091007 |